<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>333</serviceExecutionTime><Drug id="9621"><DrugName>spirogermanium hydrochloride</DrugName><DrugNamesKey><Name id="42759988">spirogermanium</Name></DrugNamesKey><DrugSynonyms><Name><Value>spirogermanium hydrochloride</Value></Name><Name><Value>NSC-192965</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>spirogermanium</Value><Types><Type>BANN</Type><Type>INN</Type></Types></Name><Name><Value>S-99-A</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>spiro-32</Value></Name><Name><Value>41992-22-7</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>41992-23-8</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="15894">Unimed Pharmaceuticals Inc</CompanyOriginator><CompaniesSecondary><Company id="15894">Unimed Pharmaceuticals Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="9621" type="Drug"><TargetEntity id="90009" type="siDrug">Spirogermanium hydrochloride</TargetEntity><TargetEntity id="133052" type="siDrug">Spirogermanium</TargetEntity></SourceEntity><SourceEntity id="15894" type="Company"><TargetEntity id="4295911739" type="organizationId">Unimed Pharmaceuticals LLC</TargetEntity></SourceEntity><SourceEntity id="213" type="ciIndication"><TargetEntity id="G35" type="ICD10"></TargetEntity><TargetEntity id="10028245" type="MEDDRA"></TargetEntity><TargetEntity id="D009103" type="MeSH"></TargetEntity><TargetEntity id="-1241225595" type="omicsDisease"></TargetEntity><TargetEntity id="112" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="291" type="ciIndication"><TargetEntity id="10039073" type="MEDDRA"></TargetEntity><TargetEntity id="D001172" type="MeSH"></TargetEntity><TargetEntity id="-1391695545" type="omicsDisease"></TargetEntity><TargetEntity id="749" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="213">Multiple sclerosis</Indication><Indication id="291">Rheumatoid arthritis</Indication><Indication id="651">Cancer</Indication></IndicationsSecondary><ActionsSecondary><Action id="1545">Anticancer</Action><Action id="1596">Immunomodulator</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2017-09-01T09:27:31.000Z</LastModificationDate><ChangeDateLast>2013-04-22T00:00:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;Unimed has discontinued the development of &lt;ulink linkID="9621" linkType="Drug"&gt;spirogermanium hydrochloride&lt;/ulink&gt; for the treatment of cancer, rheumatoid arthritis and multiple sclerosis [&lt;ulink linkID="205194" linkType="reference"&gt;205194&lt;/ulink&gt;]. It had been in phase II trials [&lt;ulink linkID="172347" linkType="reference"&gt;172347&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="15894">Unimed Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="651">Cancer</Indication><StatusDate>1995-01-01T00:00:00.000Z</StatusDate><Source id="205194" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15894">Unimed Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="213">Multiple sclerosis</Indication><StatusDate>1995-01-01T00:00:00.000Z</StatusDate><Source id="205194" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15894">Unimed Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>1995-01-01T00:00:00.000Z</StatusDate><Source id="205194" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="15894">Unimed Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="651">Cancer</Indication></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15894">Unimed Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="213">Multiple sclerosis</Indication></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15894">Unimed Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><StructureSmiles><Smiles>CC[Ge]1(CCC2(CCN(C2)CCCN(C)C)CC1)CC.Cl.Cl</Smiles><Smiles>CC[Ge]1(CCC2(CCN(C2)CCCN(C)C)CC1)CC</Smiles></StructureSmiles><PatentFamilies><PatentFamily id="1980445" number="US-03825546" title="Silicon And Germanium Substituted Azaspiranes"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Geschickter Fund For Medical Res" id="1009854"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>